Latest news with #Zynex
Yahoo
23-05-2025
- Business
- Yahoo
Here's Why Zynex (ZYXI) Fell in Q1
Rewey Asset Management, an investment management company, released its 'RAM Smid Composite' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The composite declined 6.97% in Q1 2025, trailing a 5.83% decline for the benchmark Russell 2500 Value Total Return Index. Larger-cap stocks outperformed smaller ones in 1Q25, with the Russell 3000 TR value up 1.64% and the Russell 2000 TR value down 7.74%, while the RAM Smid composite is biased towards smaller-cap stocks. The significant market theme in Q1 2025 was the uncertainty surrounding the potential negative economic effects of Trump's tariffs. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Rewey Asset Management highlighted stocks such as Zynex, Inc. (NASDAQ:ZYXI). Zynex, Inc. (NASDAQ:ZYXI) is a medical device manufacturer. The one-month return of Zynex, Inc. (NASDAQ:ZYXI) was -6.43%, and its shares lost 78.56% of their value over the last 52 weeks. On May 22, 2025, Zynex, Inc. (NASDAQ:ZYXI) stock closed at $2.30 per share with a market capitalization of $68.189 million. Rewey Asset Management stated the following regarding Zynex, Inc. (NASDAQ:ZYXI) in its Q1 2025 investor letter: "Zynex, Inc. (NASDAQ:ZYXI) was our worst performer in the quarter, as the company announced that its top insurance payor was pausing reimbursement while it reviewed the company's shipping practices for consumable supplies. The company continues to ship consumables as requested during the review and has stated they are compliant with the relationship post an audit 2-years ago. While we did trim our position on this news, the leading pillar of our investment case, the introduction of the company's NiCO pulse laser oximeter in late 2025, remains in-tact. This pulse oximeter uses a laser to measure blood oxygen levels during surgery and is more accurate than current light-based estimated readings which are obstructed by pigment levels in skin. Leading reviews of the NiCO device have been positive, and we think it could become the standard of care." A close-up view of medical devices, electrical stimulation electrodes, and batteries. Zynex, Inc. (NASDAQ:ZYXI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held Zynex, Inc. (NASDAQ:ZYXI) at the end of the fourth quarter compared to 10 in the third quarter. In Q1 2025, Zynex, Inc. (NASDAQ:ZYXI) reported net revenue of $26.6 million compared to $46.5 million in Q1 2024. While we acknowledge the potential of Zynex, Inc. (NASDAQ:ZYXI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
19-05-2025
- Business
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) and reminds investors of the May 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements Share Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that Zynex shipped products, including electrodes, in excess of need; (2) that, as a result of this practice, the Company inflated its revenue; (3) that the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) that, as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On June 4, 2024, medical journal STAT published a report on Zynex entitled 'How a device maker inundated pain patients with unwanted batteries and surprise bills.' The report claimed Zynex engaged in an 'oversupplying scheme' by sending inordinate amounts of monthly supplies like electrode pads and batteries in order to 'bill insurers for thousands of dollars more than it otherwise could.' The report further revealed that, as a result of this practice, insurers were 'kicking the company out of network.' On this news, Zynex's stock price fell $0.50 per share, or 5%, to close at $9.35 per share on June 4, 2024, on unusually heavy trading volume. On March 11, 2025, after the market closed, Zynex reported its fourth quarter and full year 2024 financial results, revealing a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' Zynex further revealed 'Tricare has temporarily suspended payments as they review prior claims.' Tricare is the health insurance program for the U.S. military. On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zynex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zynex, Inc. class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Associated Press
18-05-2025
- Business
- Associated Press
DEADLINE TOMORROW: Berger Montague Advises Zynex (ZYXI) Investors to Contact the Firm Before May 19, 2025
Philadelphia, Pennsylvania--(Newsfile Corp. - May 18, 2025) - Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the 'Class Period'). Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights,CLICK HERE. Zynex, headquartered in Englewood, CO, is a medical device company that makes electrotherapy devices for pain management and rehabilitation. According to the lawsuit, Defendants failed to disclose to investors that: (1) Zynex shipped products, including electrodes, in excess of demand; (2) as a result, Zynex was able to inflate its revenue; (3) the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; and (4) thus, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government. On June 4, 2024, medical journal STAT published a report titled 'How a device maker inundated pain patients with unwanted batteries and surprise bills,' which claimed that Zynex engaged in an 'oversupplying scheme' by sending inordinate amounts of supplies, such as electrode pads and batteries, in order to 'bill insurers for thousands of dollars more than it otherwise could.' The report further revealed that, as a result of this practice, insurers were 'kicking the company out of network.' On this news, Zynex's stock price fell $0.50 per share, or 5%, to close at $9.35 per share on June 4, 2024. On March 11, 2025, Zynex reported Q4 and full-year 2024 financial results, revealing a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' Zynex further revealed " Tricare [health insurance program for the U.S. military] has temporarily suspended payments as they review prior claims.' On this news, Zynex's stock price fell $3.59 per share, or 51%, to close at $3.41 per share on March 12, 2025. To learn your rights or for more information,CLICK HEREor please contact Berger Montague: Andrew Abramowitz at[email protected]or (215) 875-3015, or Peter Hamner at[email protected]. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member. Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States. Contact: Andrew Abramowitz, Senior Counsel Berger Montague (215) 875-3015 [email protected] Peter Hamner Berger Montague PC [email protected] To view the source version of this press release, please visit
Associated Press
18-05-2025
- Business
- Associated Press
ZYXI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - May 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the 'Class Period'), of the important May 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zynex class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, Defendants failed to disclose to investors that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, Zynex inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants' positive statements about the Zynex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zynex class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Associated Press
17-05-2025
- Business
- Associated Press
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) and reminds investors of the May 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that Zynex shipped products, including electrodes, in excess of need; (2) that, as a result of this practice, the Company inflated its revenue; (3) that the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) that, as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On June 4, 2024, medical journal STAT published a report on Zynex entitled 'How a device maker inundated pain patients with unwanted batteries and surprise bills.' The report claimed Zynex engaged in an 'oversupplying scheme' by sending inordinate amounts of monthly supplies like electrode pads and batteries in order to 'bill insurers for thousands of dollars more than it otherwise could.' The report further revealed that, as a result of this practice, insurers were 'kicking the company out of network.' On this news, Zynex's stock price fell $0.50 per share, or 5%, to close at $9.35 per share on June 4, 2024, on unusually heavy trading volume. On March 11, 2025, after the market closed, Zynex reported its fourth quarter and full year 2024 financial results, revealing a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' Zynex further revealed 'Tricare has temporarily suspended payments as they review prior claims.' Tricare is the health insurance program for the U.S. military. On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zynex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zynex, Inc. class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
